Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e...

103
Giorgio Sesti Università “Magna Graecia” di Catanzaro ITALY Sulfoniluree e glinidi: pro e contro

Transcript of Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e...

Page 1: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Giorgio Sesti

Università “Magna Graecia” di CatanzaroITALY

Sulfoniluree e glinidi: pro e contro

Page 2: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

T2DM anti-hyperglycaemic therapy: general recommendations

Diabetes Care 35:1364-1379, 2012; Diabetologia 55:1577-1596, 2012

Page 3: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

Page 4: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Weighted Mean Absolute Difference in Hemoglobin A1c Level between Groups for Randomized, Controlled Trials Comparing Oral Diabetes Medications with

Placebo or Diet

Bolen S. et al. Ann Intern Med 147:386-399, 2007

UKPDS 33 (10 years follow-up)

Chlorpropamide vs. Conventional -1.2%

UKPDS 33 (10 years follow-up)

Glibenclamide vs. Conventional -0.7%

Page 5: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Weighted Mean Absolute Difference in Hemoglobin A1c Level between Groups for Randomized, Controlled Trials Comparing Oral Diabetes Medications with

Placebo or Diet

Bolen S. et al. Ann Intern Med 147:386-399, 2007

-0,97

-1,14

-1,52

-1,32

-0,77

-1,6

-1,4

-1,2

-1

-0,8

-0,6

-0,4

-0,2

0

Pioglitazone Metformin SU Repaglinide Acarbose

Page 6: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Bolen S. et al. Ann Intern Med 147:386-399, 2007

Weighted mean difference in HbA1c with use of oral medications for T2DM

Page 7: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Monami M. et al Diabetes Res Clin Pract 79:196-203, 2008

Effect of hypoglycemic agents as add-on therapy to metformin in randomized, placebo-controlled clinical trials

-0.61

-0.85

-0.42

-0.70

Page 8: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Phung OJ et al. JAMA 303:1410-1418, 2010

Meta-analysis of RCTs with at least 3 months’ duration, evaluating antidiabetic drugs added to metformin

Page 9: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Pooled between-group differences in HbA1c level with monotherapy and combination therapies. A network meta-analysis of randomized trials at least 24 weeks in duration

Bennett W L et al. Ann Intern Med 154 602-613, 2011

Page 10: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Network meta-analysis of pairwise comparisons of randomized controlled trials evaluating the use of anti-hyperglycemic agents in addition to metformin vs.

placebo: mean change from baseline in A1C

Liu S-C et al. Diabetes Obes and Metab 14: 810–820, 2012

-0,82

-0,71

-0,82

-0,66-0,69

-1,02

-0,88

-1,07

-1,2

-1

-0,8

-0,6

-0,4

-0,2

0

SU Glinides TZDs Acarbose DPP-4 GLP-1 Basal Biphasicinhibitors agonists insulin insulin

Me

an

ch

an

ge

fro

m b

ase

lin

e i

n A

1C

le

ve

l

Page 11: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Proportion of patients at HbA1c target <7% with eight classes of antidiabetic drugs in type 2 diabetes: systematic review of 218 randomized controlled trials

with 78 945 patients

Esposito K. et al. Diabetes Obes and Metab 14: 228–233, 2012

42

48,2

39,2

33,2

29,9

39

45,7

38,9

34,436,3

50,2

-5

5

15

25

35

45

55

Met SU Glinides TZDs Acarbose DPP-4 GLP-1 Basal Biphasic Prandial Basal/inhibitors agonists insulin insulin insulin Bolus

Pro

po

rtio

n o

f p

ati

en

ts w

ho

ach

ieve

d t

he

Hb

A1

c g

oa

l (%

)

Page 12: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Effect of antihyperglycemic agents added to metformin and a sulfonylurea on glycemic control in T2DM: a network meta-analysis

Gross JL et al. Ann Intern Med 154:672-679, 2011

-1,01

-1,08

-0,95 -0,94

-0,70

-1,2

-1

-0,8

-0,6

-0,4

-0,2

0

GLP-1R agonists Insulin TZDs DPP-4 I Acarbose

Page 13: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

McIntosh B et al. Open Medicine 5:e35, 2011

Mixed-treatment comparison showing the effect of adding second-line antihyperglycemic agents vs. placebo to metformin on change from baseline in

HbA1c

Page 14: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

McIntosh B et al. Open Medicine 5:e35, 2011

Mixed-treatment comparison showing the effect of adding second-line antihyperglycemic agents vs. placebo to metformin on odds of at least 1 event

of overall hypoglycemia

Page 15: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

McIntosh B et al. Open Medicine 5:e35, 2011

Mixed-treatment comparison showing the effect of adding second-line antihyperglycemic agents vs. placebo to metformin on change from baseline in

body weight

Page 16: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Meta-analysis of RCTs with at least 3 months’ duration, evaluating antidiabetic drugs added to metformin

Phung OJ et al. JAMA 303:1410-1418, 2010

Change in HbA1c Goal Achieved (<7.0%)

Page 17: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

Page 18: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

UKPDS 16. Diabetes 44:1249–1258 1995. Lebovitz 7:139–153, 1999

UKPDS: β-cell function progressively declines

Diet (n = 110)Sulfonylureas(n = 511)

Metformin (n = 159)

Years from diagnosis

-c

ell

fu

ncti

on

(%

, H

OM

A)

Diabetes diagnosis

0

20

40

60

80

100

–5 –4 –3 –2 –1 0 1 2 3 4 5 6

Extrapolation of β-cell function prior to diagnosis

Page 19: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

ADOPT: β-Cell Function According to Treatment Group

Kahn et al. N Engl J Med 355:2427-2443, 2006

Page 20: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

ADOPT: Baseline adjusted geometric mean levels in the full cohort within each treatment group over 4 years of follow-up for OGTT-derived dynamic measure

of the early insulin response

Kahn SE et al. Diabetes 60:1552–1560, 2011

Rate of change from 0.5 to 4 years(% per year)

Rosiglitazone: -6.0%Metformin: -7.4%

Glyburide: -11.1%; P<0.0001 vs. Rosi

Page 21: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

In vitro and ex vivo data

Page 22: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

1,9

3,2 3,3 3,4

4,9

4,6

3,83,6

0

1

2

3

4

5

6

Control Glimepiride (10 µM) Glibenclamide (10 µM) Chlorpropamide (10 µM)

3.3 mmol/l glucose

16.7 mmol/l glucose

Insulin release (% of insulin content) in response to acute glucose stimulation from human islets exposed for 24-h to sulphonylureas (n = 10)

Del Guerra S et al. J Diabetes Complications 19:60-4, 2005

Page 23: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Impaired insulin release (% of insulin content) in human islets pre-exposed for 24-h to sulphonylureas was reverted by an additional 48-h incubation in drug-free conditions

22,2

2,11,9

3,9

3,53,6 3,6

0

0,5

1

1,5

2

2,5

3

3,5

4

4,5

Control Glimepiride (10 µM) Glibenclamide (10 µM) Chlorpropamide (10 µM)

3.3 mmol/l glucose

16.7 mmol/l glucose

Del Guerra S et al. J Diabetes Complications 19:60-4, 2005

Page 24: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Remedi MS et al. PLoS Med 5: e206, 2008

Chronic Antidiabetic Sulfonylureas In Vivo:Reversible Effects on Mouse Pancreatic beta-Cells

Page 25: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Chronic Antidiabetic Sulfonylureas In Vivo:Reversible Effects on Mouse Pancreatic beta-Cells

Remedi MS et al. PLoS Med 5: e206, 2008

Page 26: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Remedi, MS et al. PLoS Med 5: e206, 2008

Absence of beta-cell apoptosis in islets from control or high dose (0.25 and 2.5 mg/pellet) glibenclamide-pelleted mice after 56 days

Page 27: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

ADOPT: β-Cell Function According to Treatment Group

Kahn et al. N Engl J Med 355:2427-2443, 2006

washout

Page 28: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Effects of repaglinide, nateglinide, and glibenclamide on beta-cell apoptosis in human islets

Maedler K et al.J Clin Endocrinol Metab 90: 501–506, 2005

Control repaglinide nateglinide glibenclamide

Page 29: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Gliclazide protects human islet beta-cells from apoptosis induced by intermittent high glucose

Del Guerra S et al. Diabetes Metab Res Rev 23: 234–238, 2007

Beta-cell apoptosis in human islets exposed for 5 days to 5.5 mmol/L glucose (NG), alternating 5.5 and 16.7 mmol/L glucose (HG), HG with gliclazide or HG with glibenclamide

Page 30: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

3,1

1,8

2,2

1,5

0

0,5

1

1,5

2

2,5

3

3,5

Low glucose (control) High glucose High glucose +Gliclazide (10 µM)

High glucose +Glibenclamide (1 µM)

Insulin release (% of insulin content) in response to acute glucose stimulation from human islets exposed for 5 days to 5.5 mmol/L glucose (NG), alternating 5.5 and 16.7

mmol/L glucose (HG), HG with gliclazide or HG with glibenclamide

Del Guerra S et al. Diabetes Metab 35:293-298, 2009

P<0.05

Page 31: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Viability of MIN6 beta cell exposed to H2O2 in the presence of gliclazide (5 µmol/L) or glibenclamide (5 µmol/L)

Kimoto K et al. Biochem Biophys Res Commun 303:112-9, 2003

Page 32: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Exposure to gliclazide, but not glibenclamide, significantly induced expression of PDX-1, a fundamental beta-cell differentiation

transcription factor, and Ki67, a marker of proliferation in human islets

Del Guerra S et al. Diabetes Metab 35:293-298, 2009

Page 33: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

Page 34: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Ch

an

ge

in

Hb

A1

c (

%)

TIME (years)

50 1 2 3 4 106

-2

-1

0

1

Periscope (n=178)

Glyburide

Tan (n=249)

Gliclazide

Alvarsson (n=39)GLYAlvarsson (n=48)x

Charbonnel (n=317)

x

x

x

xx

Gliclazide

SU

RECORD (n=301)

SU

Chicago (n=232)

Glimpepiride

Hanefeld (n=250)Glyburide

ADOPT (n=1,456)

Glyburide

UKPDS (n=1,573)

Glyburide

DeFronzo R A Diabetes 58:773-795, 2009

Summary of studies examining the effect of sulfonylurea (SU) treatment vs. placebo or vs. active-comparator on A1C in type 2 diabetic subjects

Page 35: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

cohort, median data

ADA goal

Lancet 352:837-853, 1998

UKPDS 33: Over time, glycaemic control deteriorates

06

7

8

9

0 2 4 6 8 10

Hb

A1

c(%

)

Years from randomisation

Glibenclamide (n=615)

Chlorpropamide (n=619)

Conventional (n=896)

Insulin (n=911)

Page 36: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

25

12

9

47

37

28

53

39

28

47

29

20

0

10

20

30

40

50

60

UKPDS 49: Proportion of patients who attain HbA1c < 7.0%

%

53

Turner RC et al. JAMA 281: 2005-2012, 1999

Conventional

Insulin

Chlorpropamide

Glibenclamide

3 years 9 years6 years

Page 37: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

cohort, median values

06

7

8

9

0 2 4 6 8 10

Hb

A1

c(%

)

Years from randomisation

Chlorpropamide (n=265)

Conventional (n=411)

Glibenclamide (n=277)

Insulin (n=409)

Metformin (n=342)

UKPDS 34: Over time, glycaemic control deteriorates in overweight T2DM

ADA goal

UKPDS 34. Lancet 352:854–865, 1998

Page 38: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

23

12 11

34

37

24

51

33

20

40

23 22

44

34

13

0

10

20

30

40

50

60

UKPDS 49: Proportion of patients who attain HbA1c < 7.0%

%

53

Turner RC et al. JAMA 281: 2005-2012, 1999

Diet

Insulin

Chlorpropamide

Glibenclamide

Metformin

3 years 9 years6 years

Page 39: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Kahn et al. N Engl J Med 355:2427-2443, 2006

ADOPT: Treatments and HbA1c

Page 40: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

8.0

6.0

7.5

7.0

6.5

Time (years)

0

0 2 3 4 51

Rosiglitazone (n=1456)

Metformin (n=1454)

Glibenclamide (n=1441)

Rosiglitazone vs. Metformin –0.13, P=0.002

Rosiglitazone vs. Glibenclamide –0.42, P<0.001

Kahn et al. N Engl J Med 355:2427-2443, 2006

Hb

A1

c (

%)

ADA goal

ADOPT: Treatments and HbA1c

Page 41: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Time course of HbA1C in ADOPT redrawn to show average blood glucose control over the first 3 years

Al-Ozairi E et al. Diabetes Care 30: 1677-1680, 2007

Page 42: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Time course of HbA1C in ADOPT redrawn to show average blood glucose control over the first 3 years

Al-Ozairi E et al. Diabetes Care 30: 1677-1680, 2007

Page 43: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Treatment effects on A1C by SU class, dose, and time: a meta-analysis

Sherifali D et al. Diabetes Care 33:1859–1864, 2010

Glipizide

Glimepiride

Glibenclamide

Page 44: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

1.6%

57.1%

90.5%

1.9%

Gliclazide MR

Other Sulfonylureas

67.0%73.8%Metformin

24.1%40.5%Insulin

Standard (n=4741)

Intensive (n=4828)

10.9%16.9%Thiazolidinediones

2.8%1.2%Glinides

12.9%19.1%Acarbose

Randomized treatment

ADVANCE: Glucose control drugs at end of follow-up

N Engl J Med 358:2560-2572, 2008

Page 45: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Mean HbA1c

at final visit

7.3 %

6.5%

Me

an

Hb

A1

c (

%)

5.0

5.5

6.0

6.5

7.0

7.5

8.0

8.5

9.0

9.5

10.0

Follow-up (Months)

0 6 12 18 24 30 36 42 48 54 60 66

Δ 0.67% (95% CI 0.64 – 0.70); P<0.0001

Standard

Intensive (Gliclazide MR)

ADVANCE collaborative group. N Engl J Med 358:2560-72, 2008

Hemoglobin A1c : ADVANCE

Page 46: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

ORIGIN Trial Investigators, N Engl J Med 367: 319-28, 2012

Drug Use at Study End

Insulin Glargine Standard Care P

No Oral Agents (%) 35 19 <0.001

1 Oral Agents (%) 51 39 <0.001

2 Oral Agents (%) 12 28 <0.001

> 3 Oral Agents (%) 3 14 <0.001

Rapid insulin (%) 2 5 <0.001

Any Insulin (%) 80 11 <0.001

Metformin (%) 47 60 <0.001

Sulfonylurea (%) 25 47 <0.001

Page 47: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Median A1C Levels ORIGIN trial

6,4

5,96 6

6,16,2

6,36,2

6,4

6,26,3

6,4 6,46,5 6,5 6,5

5,0

6,0

7,0

0 1 2 3 4 5 6 7

A1

C (

%)

Year

Glargine

Standard

ORIGIN Trial Investigators, N Engl J Med 367: 319-28, 2012

Median follow-up = 6.2 years

Page 48: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Satoh J et al. Diabetes Res. Clin. Pract 70: 291–297, 2005

Kaplan- Meier curve of the period until the start of insulin treatment from gliclazide or glibenclamide treatment: retrospective analysis in Japanese patients

Gliclazide

Glibenclamide

Page 49: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Seck T et al. Int J Clin Pract 64:562-76, 2010

Sitagliptin vs. Glipizide as add-on to Metformin:Sustained reduction in HbA1c over 2 year

(n=256)

(n=248)

Glipizide –0.51%

Sitagliptin –0.54%

The rise in HbA1c from week 24 to the end of the 2nd year was less with sitagliptin treatment compared with glipizide [coefficient of durability (95%CI):

0.16% ⁄ year (0.10, 0.21) vs. 0.26% ⁄ year (0.21,0.31) respectively; between-group difference in COD (95% CI) = -0.10% ⁄ year (-0.16, -0.05)]

Page 50: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Serum C-peptide profiles during the nine-point meal tolerance test at baseline and following a 4- to 7-day wash off of study drug following 2 years of

treatment with sitagliptin or glipizide added to metformin therapy

Seck T et al. Int J Clin Pract 64:562-76, 2010

Page 51: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Baseline and study endpoint results for indices of beta-cell function from the 9-point meal tolerance tests administered following a 4- to 7-day wash off of study drug after 2

years of treatment with sitagliptin or glipizide added to metformin therapy

Seck T et al. Int J Clin Pract 64:562-76, 2010

Page 52: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Time course of mean HbA1c during 117 weeks of treatment, with vildagliptin plus metformin or glimepiride (up to 6 mg/day) plus metformin in patients aged <65 years

Matthews DR et al. Diabetes Obes Metab12: 780–789, 2010.

−0.1%

−0.1%

Sustainability of treatment effect: the mean time that patients treated with vildagliptin or glimepiride

maintained their initial response (no increase of >0.3% above the nadir during the first 6 months) was 292 vs. 258 days, respectively (P<0.001)

Page 53: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Change in HbA1c over time

Göke B, et al. Int J Clin Pract 67:307-16, 2013

Page 54: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Kaplan–Meier analysis of time to discontinuation owing to insufficient glycemic control

Göke B, et al. Int J Clin Pract 67:307-16, 2013

Page 55: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

Page 56: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Glitazone-like action of glimepiride and glibenclamidein primary human adipocytes

Mayer P. et al. Diabetes Obes and Metab 13: 791–799, 2011

Page 57: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

UKPDS 33: Treatments and weight change

cohort, mean data

Years from randomisation

-2.5

0.0

2.5

5.0

7.5

10.0

0 2 4 6 8 10

We

igh

t (k

g) Chlorpropamide

Conventional

Insulin

Glibenclamide

UKPDS 33 Lancet 352:837-853, 1998

Page 58: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

cohort, mean values

-5

0

5

10

0 2 4 6 8 10

We

igh

t ch

an

ge

(k

g)

Years from randomisation

Chlorpropamide

Conventional

Metformin

UKPDS 34: Treatments and weight change in overweight T2DM

Insulin

Glibenclamide

UKPDS 34. Lancet 352:854-865, 1998

Baseline = 85 kg

Page 59: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

ADOPT: Treatments and weight change

Kahn et al. N Engl J Med 355:2427-2443, 2006

Page 60: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Bolen S. et al. Ann Intern Med 147:386-399, 2007

Weighted Mean Absolute Difference in Body Weight between Groups for Randomized, Controlled Trials Comparing Oral Diabetes Medications with

Placebo or Diet

Page 61: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Bolen S. et al. Ann Intern Med 147:386-399, 2007

Weighted Mean Absolute Difference in Body Weight between Groups for Randomized, Controlled Trials Comparing Oral Diabetes Medications with

Placebo or Diet

33,1

0,3

3,8

-0,1-0,5

0

0,5

1

1,5

2

2,5

3

3,5

4

Pioglitazone Rosiglitazone Metformin SU Acarbose

Page 62: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Meta-analysis of RCTs with at least 3 months’ duration, evaluating antidiabetic drugs added to metformin

Phung OJ et al. JAMA 303:1410-1418, 2010

Change in Body Weight

Page 63: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Network meta-analysis of pairwise comparisons of randomized controlled trials evaluating the use of anti-hyperglycemic agents in addition to metformin vs.

placebo: Mean change from baseline in body weight

Liu S-C et al. Diabetes Obes and Metab 14: 810–820, 2012

2,17

1,4

2,46

-1,01

0,23

-1,66

1,38

3,41

-2

-1

0

1

2

3

4

SU Glinides TZDs Acarbose DPP-4 GLP-1 Basal Biphasicinhibitors agonists insulin insulin

Me

an

ch

an

ge

fro

m b

ase

lin

e i

n b

od

y w

eig

ht

Page 64: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Bennett W L et al. Ann Intern Med 154 602-613, 2011

Pooled between-group difference in body weight with monotherapy and combination therapies. A network meta-analysis of randomized trials at least 24 weeks in duration

Page 65: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

1.6%

57.1%

90.5%

1.9%

Gliclazide MR

Other Sulfonylureas

67.0%73.8%Metformin

24.1%40.5%Insulin

Standard (n=4741)

Intensive (n=4828)

10.9%16.9%Thiazolidinediones

2.8%1.2%Glinides

12.9%19.1%Acarbose

Randomized treatment

ADVANCE: Glucose control drugs at end of follow-up

N Engl J Med 358:2560-2572, 2008

Page 66: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Difference 0.75 kg (0.56, 0.94) P<0.0001

Standard

Intensive

We

igh

t (k

g)

75

76

77

78

79

80

Follow-up (months)

0 6 12 18 24 30 36 42 48 54 60

ADVANCE: Difference in body weight at end of follow-up

N Engl J Med 358:2560-2572, 2008

Page 67: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

Page 68: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

0,7

0,1

0,4

0,1

0,6

0,4

0,7

0,1

2,5

0,6 0,6

0,1

0

0,5

1

1,5

2

2,5

3

UKPDS 34 UKPDS 33 ADVANCE ADOPT

Rate of severe hypoglycemic events

Ra

te o

f se

ve

re h

yp

og

lyce

mic

eve

nts

(e

ve

nt

pe

r 1

00

pa

tie

nts

pe

r ye

ar)

Chlorpropamide

Conventional

Metformin

Glibenclamide

Intensive Therapy

Standard Therapy

Rosiglitazone

Page 69: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

0,1%

1,2%

0,3%

3,8%

5,5%

0

1

2

3

4

5

6

*Hypoglycaemia: temporary incapacity or requiring medical help

Wright AD et al. J Diabetes Complications.20:395-401, 2006

Diet Sulfonylurea Metformin Basal insulin

Basal + prandial insulin

Pa

tie

nts

(%

)

Annual percentage of patients reporting ≥1 hypoglycaemic event*

UKPDS: prevalence of hypoglycaemia in Type 2 diabetes

Page 70: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Network meta-analysis of pairwise comparisons of randomized controlled trials evaluating the use of anti-hyperglycemic agents in addition to metformin vs.

placebo: At least one event of overall hypoglycaemia (odds ratio)

Liu S-C et al. Diabetes Obes and Metab 14: 810–820, 2012

8,86

10,51

0,45 0,41,13 0,92

4,77

17,78

0

2

4

6

8

10

12

14

16

18

20

SU Glinides TZDs Acarbose DPP-4 GLP-1 Basal Biphasicinhibitors agonists insulin insulinA

t le

ast

on

e e

ve

nt

of

ove

rall

hyp

og

lyca

em

ia(o

dd

s r

ati

o)

Page 71: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Pooled odds of mild or moderate hypoglycemia with monotherapy and combination therapies. A network meta-analysis of randomized trials at least 24 weeks in duration

Bennett W L et al. Ann Intern Med 154 602-613, 2011

Page 72: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Bolen S. et al. Ann Intern Med 147:386-399, 2007

Pooled hypoglycemia results for randomized trials, by drug comparison

Page 73: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Meta-analysis of RCTs with at least 3 months’ duration, evaluating antidiabetic drugs added to metformin

Phung OJ et al. JAMA 303:1410-1418, 2010

Change in Overall Hypoglycemia

Page 74: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

Page 75: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

UKPDS 33: Microvascular events (Retinopathy and nephropathy)

UKPDS 33 Lancet 352:837-853, 1998

favours intensive

favours conventionalRR 0.1 1 10

Chlorpropamide (n=619)

Glibenclamide (n=615)

Insulin (n= 911)

0.86 (0.63-1.17)

0.66 (0.47-0.93)

0.70 (0.52-0.93)

P = 0.33

P = 0.017

P = 0.015

Page 76: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

UKPDS 33: Microvascular events (Retinopathy and nephropathy)

UKPDS 33 Lancet 352:837-853, 1998

favours intensive

favours conventionalRR 0.1 1 10

Chlorpropamide (n=619)

Glibenclamide (n=615)

P = 0.33

P = 0.017

0.86 (0.63-1.17)

0.66 (0.47-0.93) P=0.017

P=0.33

Page 77: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Intensive (SU/Ins) vs. Conventional glucose control

(Photocoagulation, vitreous haemorrhage, renal failure)

HR (95%CI)

UKPDS 80: Extended effects of improved glycemic control in patients with newly diagnosed type 2 diabetes- Microvascular Disease Hazard Ratio

Holman R.R. et al. N Engl J Med 359:1577-1589, 2008

Page 78: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Microvascular 526 605 14% (3 to 23)

New or worsening nephropathy 230 292 21% (7 to 34)

New or worsening retinopathy 332 349 5% (-10 to 18)

Number of patients with event

Intensive Standard(n=5,571) (n=5,569)

Relative riskreduction (95% CI)

FavorsIntensive

FavorsStandard

Hazard ratio0.5 1.0 2.0

†P=0.01

‡P=0.006

N Engl J Med 358:2560-2572, 2008

ADANCE: Major microvascular events

Page 79: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

a. Randomized clinical trials (RCT)

b. Registry studies

c. Meta-analisi

Page 80: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

0.0

0.1

0.2

0.3

0.4

0 3 6 9 12 15

Pro

po

rtio

n o

f p

ati

en

ts w

ith

eve

nt

Years from randomisation

Conventional (n=896)

Chlorpropamide (619)

Glibenclamide (615)

Insulin (911)

UKPDS 33 Lancet 352:837-853, 1998

UKPDS 33: Myocardial Infarction

Intensive vs. conventionalRelative Risk 0.84 (0.71-1.00)

P = 0.052

Glibenclamide vs. conventionalRelative Risk 0.78 (0.60-1.01)

P = 0.056

Page 81: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

(Fatal or non-fatal myocardial infarction or sudden death)

Intensive (SU/Ins) vs. Conventional glucose control

HR (95%CI)

Myocardial Infarction Hazard Ratio

Holman R.R. et al. N Engl J Med 359:1577-1589, 2008

Page 82: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Intensive (SU/Ins) vs. Conventional glucose control

HR (95%CI)

All-cause Mortality Hazard Ratio

Holman R.R. et al. N Engl J Med 359:1577-1589, 2008

Page 83: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Relative risk reduction 6% (95% CI: -6 to 16%)

P=0.32

Follow-up (months)

25

20

15

10

5

0

Standard

Intensive

0 6 12 18 24 30 36 42 48 54 60 66

N Engl J Med 358:2560-2572, 2008

Major macrovascular events defined as death from CV causes, nonfatal MI, or nonfatal stroke: ADVANCE

Page 84: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

ADOPT: CV Adverse Events According to Treatment Group

Kahn et al. N Engl J Med 355:2427-2443, 2006

Page 85: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Mellbin LG et al. Diabetologia 54:1308–1317, 2011

Prognostic implications of glucose-lowering treatment in patients with acute MI and T2DM : extended follow-up (median 4.1yrs) of the DIGAMI 2 Study

Page 86: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Odds ratio for major CV events with SU: a meta‐analysis of RCTs

Monami M et al. Diabetes Obes Metab 15:938–953, 2013

Page 87: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Odds ratio for all‐cause mortality with SU: a meta‐analysis of RCTs

Monami M et al. Diabetes Obes Metab 15:938–953, 2013

Page 88: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

a. Randomized clinical trials (RCT)

b. Registry studies

c. Meta-analisi

Page 89: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Zeller M et al. J Clin Endocrinol Metab 95: 4993–5002, 2010

Impact of Preadmission Sulfonylureas on Mortality and CV Outcomes in Diabetic Patients with Acute Myocardial Infarction: The French registry on Acute ST-elevation and non ST-elevation Myocardial Infarction (FAST-MI)

Patients on SU had a lower risk of in-hospital mortality, compared with patients without sulfonylurea therapy before admission

OR= 0.50 (95% CI 0.27– 0.94), P=0.03

Page 90: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Overall mortality in 23915 patients with type 2 diabetes initiators of monotherapy with metformin (12774), glipizide (4325), glyburide (4279) or glimepiride (2537)

Pantaleone K M et al. Diabetes Obes and Metab 14: 803–809, 2012

Glyburide vs. Metformin HR: 1.59 (95%CI 1.35-1.88)

Glipizide vs. Metformin HR: 1.64 (95%CI 1.39-1.94)

Glimepiride vs. Metformin HR: 1.68 (95%CI 1.37-2.06)

Metformin

Page 91: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Risk of acute coronary events associated with glyburide compared with gliclazide use in patients with type 2 diabetes: a nested case–control study

Abdelmoneim As et al. Diabetes Obes and Metab 2013

•Adjusted odds ratio for baseline drug use and co-morbidities;• past exposure, a dispensation for glyburide or gliclazide more than 120 days of the event date; • recent exposure: a dispensation for glyburide or gliclazide within 120 days of the event date.

Page 92: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Risk of coronary artery disease (CAD) using multivariable Cox models in a retrospective cohort of 20,450 T2DM patients from an electronic health record (EHR) derived clinical

data repository at the Cleveland Clinic for the period 10/24/1998 to 10/12/2006

Pantalone KM et al. Acta Diabetologica 46:145–154, 2009

Page 93: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Johnsen SP et al Am J Ther 13:134–140, 2006

First-time hospitalization for MI identified from the Hospital Discharge Registry and the Civil Registration System of North Jutland County, Denmark

Page 94: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Tzoulaki, J et al. BMJ 339:b4731, 2009

The general practice research database in the United Kingdom

comprises clinical and prescribing data from anonymised patient based

clinical records of about five million people.

Outcome: risk of myocardial infarction, congestive heart failure,

and all cause mortality associated with prescription of different classes

of oral anti-diabetes drugs among men and women with diabetes.

Mean follow-up was 7.1 years.

Page 95: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Tzoulaki, J et al. BMJ 339:b4731, 2009

Risk of a first episode of myocardial infarction among patients receiving rosiglitazone, pioglitazone, sulphonylureas, and other drugs and combinations

compared with patients receiving metformin alone

Model 1: adjusted for sex and duration of diabetes, stratified by year and quartiles of age at treatment.

Page 96: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Tzoulaki, J et al. BMJ 339:b4731, 2009

Model 1: adjusted for sex and duration of diabetes, stratified by year and quartiles of age at treatment.

Risk for all cause mortality among patients receiving rosiglitazone, pioglitazone, sulphonylureas, and other drugs and combinations compared

with patients receiving metformin alone

Page 97: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Retrospective cohort study from National Veterans Health Administration databases linked to Medicare files.

Roumie CL et al. Ann Intern Med157:601-610, 2012

Page 98: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Adjusted hazard ratios for the primary composite outcome (CVD or death) and secondary outcome (CVD alone), stratified by CVD history, age, and BMI

Roumie CL et al. Ann Intern Med157:601-610, 2012

Adjusted HR 1.21 [95% CI, 1.13 to 1.30] Adjusted HR, 1.16 [CI, 1.06 to 1.25]

Page 99: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Sulfoniluree e glinidi:

1. Controllo Metabolico

2. Effetti sulla beta cellula

3. Durability

4. Effetti sul peso

5. Ipoglicemie

6. Complicanze micro-vascolari

7. Complicanze macro-vascolari

a. Randomized clinical trials (RCT)

b. Registry studies

c. Meta-analisi

Page 100: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Comparative effects of any Sulfonylurea vs. any comparator on

cardiovascular morbidity: meta-analysis of five RCT (n=2.795)

Selvin E et a. Arch Intern Med 168:2070-2080, 2008

Page 101: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Rao AD et al. Diabetes Care 31:1672–1678, 2008

RR estimates for CVD mortality associated with combination therapy of metformin and sulfonylurea: a meta-analysis of observational studies

Page 102: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Rao AD et al. Diabetes Care 31:1672–1678, 2008

RR estimates for a composite end point of CVD hospitalizations (the first CV event fatal or nonfatal), or mortality associated with combination therapy of

metformin and sulfonylurea: a meta-analysis of observational studies

Page 103: Sulfoniluree e glinidi: pro e contro - SID Italia - Suloniluree e glinidi pro... · Sulfoniluree e glinidi: pro e contro T2DM anti-hyperglycaemic therapy: general recommendations

Flow-chart per la terapia del diabete mellito di tipo 2